Talquetamab,Teclistamab,Daratumumab
Genmab,Janssen
['talquetamab', 'tecvayli', 'carvykti', 'multiple myeloma']
asco: j&amp;j has seen response rates as high as 97% in multiple myeloma before but this time, it s for a combo of talquetamab and tecvayli, not carvykti. 
The dominant B2B news brand for biotech. Delivering news, revealing insights straight to your inbox.